Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patent

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation s

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopha

J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdu

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of Dece

Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305

The company will appeal to a federal circuit court to argue that it has limited liability due to its

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creat

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Modern

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a poten

Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their se

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared

Arbutus (ABUS) Q2 Revenue Surges 529%

Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Cons

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater C

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Gr

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensu

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

  During Thursday, 849 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

Stocks Which Set New 52-Week Low Yesterday, October 10th